What Is Compounded Semaglutide? How It Differs From Wegovy and Ozempic, and the One Problem That Is Unique to It

Three quite different things get sold under the phrase "compounded semaglutide," and telling them apart is most of the work.

The first is a lawfully compounded prescription product, made by a licensed pharmacy against a prescription for a named patient. The second is semaglutide in a salt form — semaglutide sodium or semaglutide acetate — which FDA says is a different active ingredient from the one in the approved drugs and which the agency states has no lawful basis for use in compounding at all. The third is a vial labelled "for research purposes only," sold to consumers with dosing instructions, which is not compounding in any sense and which FDA has issued warning letters over.

They look similar in a browser tab. They are not the same purchase. Here is how to tell.

The short version of what compounding is

Compounding is a real, statutory activity: federal law exempts a drug prepared for an identified individual patient, on a valid prescription, by a licensed pharmacist or physician, from the requirement to be an FDA-approved drug — in exchange for conditions on who makes it, what raw material they use, and whether the result is essentially a copy of something already commercially available. Our companion explainer walks through those conditions directly out of the statute; the mechanics are identical for both molecules, so this article does not repeat them.

Two consequences carry into everything below. Compounded drugs are not FDA-approved, which means, in FDA's own words, "the agency does not review compounded drugs for safety, effectiveness or quality before they are marketed²." And a compounded drug is not a generic — a generic must establish therapeutic equivalence to the brand under section 505(j), a bar no compounded product is held to¹.

Why a compounded semaglutide exists — and why the reason expired

Semaglutide injection was on FDA's shortage list, and while it was, compounders could supply it without the "essentially a copy" restriction closing on them. That window ended: FDA declared the shortage resolved on February 21, 2025, with enforcement discretion ending for 503A pharmacies on April 22, 2025 and for 503B outsourcing facilities on May 22, 2025 — roughly two months behind tirzepatide's identical sequence⁵⁶. Our dated timeline covers each step, including the court dates that moved it.

That the window is genuinely closed is checkable rather than asserted. A live query of FDA's own drug-shortage database on August 3, 2026 returns three semaglutide records — and every one of them is a discontinuation notice, not a shortage: Novo Nordisk's Semaglutide Tablet, posted June 4, 2026, with FDA's own note that "these products will be replaced by Ozempic (semaglutide) tablets⁷." There is no semaglutide shortage on file. Any provider still implying it is selling a shortage product is describing 2024.

The salt-form problem, which has no tirzepatide equivalent

This is the semaglutide-specific fact that almost no buyer's guide mentions, and it is the sharpest single test of whether a seller knows what it is doing.

The active ingredient in Wegovy and Ozempic is semaglutide — the base. Some compounded products contain a salt instead. FDA addresses this directly: "The agency is aware that some semaglutide products sold by compounders may be the salt forms. These salt forms, including semaglutide sodium and semaglutide acetate, are different active ingredients than are used in the approved drugs. The agency does not have information on whether these salts have the same chemical and pharmacologic properties as the active ingredient in the approved drug, and we are not aware of any lawful basis for their use in compounding³."

Read that against the statute's requirement that a compounded drug's bulk substance either meet a monograph or be "a component of drugs approved by the Secretary." Semaglutide base clears that. Semaglutide sodium and semaglutide acetate are, by FDA's own characterisation, different active ingredients — which is exactly why the agency says it knows of no lawful basis for compounding with them. If a product's certificate of analysis names a salt, that is not a nuance. It is a different drug substance than the one the trials were run on.

The oral question, which changed in 2026

"Oral semaglutide" used to be a straightforward red flag: the approved oral product (Rybelsus) was diabetes-labelled, and compounded sublingual drops were a marketing invention with no approved counterpart.

That is no longer the whole picture, and getting it right matters. The current Wegovy label now covers both an injection and Wegovy tablets, in 1.5 mg, 4 mg, 9 mg and 25 mg strengths, with a stated titration to a 25 mg once-daily maintenance dose for cardiovascular risk reduction and weight reduction in adults — and specific instructions for switching between the injection and the tablet in either direction⁴. Separately, FDA's shortage database shows Novo Nordisk discontinuing its Semaglutide Tablet products, to be "replaced by Ozempic (semaglutide) tablets⁷."

So an FDA-approved oral semaglutide for weight management now exists. That does not make a compounded sublingual drop equivalent to it — the approved tablet has a very particular administration protocol (empty stomach, morning, with no more than four ounces of water, swallowed whole, then at least 30 minutes before any food, drink, or other oral medication⁴), because oral semaglutide's absorption is the entire engineering problem the product solves. A compounded oral product that does not replicate that formulation science is not a cheaper version of the tablet. It is an untested delivery route.

How the approved products are dosed, and why that matters to a vial

The approved injections come at a much wider spread of concentrations than most people realise, and the spread is the reason a compounded vial cannot be dosed by intuition.

Wegovy's single-dose pens run from 0.25 mg/0.5 mL up to 2.4 mg/0.75 mL, with a 7.2 mg/0.75 mL high-dose presentation on top; its multi-dose FlexTouch pen holds 9.6 mg in 3 mL — 3.2 mg/mL — delivering four 2.4 mg doses⁴. Ozempic's pens run at three concentrations: 0.68 mg/mL, 1.34 mg/mL and 2.68 mg/mL⁸. That is nearly a fivefold concentration range across two brands of the same molecule, and the pen hides it from the patient by dialling a dose rather than a volume.

A compounded vial does not hide it. You draw a volume, and the milligrams in that volume depend entirely on that vial's concentration. FDA has documented what happens when that goes wrong: it has received "multiple reports of adverse events, some requiring hospitalization, that may be related to dosing errors associated with compounded injectable semaglutide products," from "patients measuring and self-administering incorrect doses of the drug, and in some cases, health care professionals miscalculating doses³." Our walk through the semaglutide label's own titration ladder covers the escalation schedule and the concentration mapping in detail; our reconstitution calculator and units-to-mg converter do the arithmetic on a dose a prescriber has already given you.

The "research use only" sellers are a separate category entirely

Worth stating plainly because the search results blur them together: FDA "has warned companies that have illegally sold unapproved drugs containing semaglutide, tirzepatide or retatrutide that are falsely labeled 'for research purposes' or 'not for human consumption.' These products have been sold directly to consumers for human use with dosing instructions³."

That is not compounding. There is no prescription, no pharmacy, no statutory exemption, and no regulatory category — the "research use only" label is the point, because it is an attempt to sit outside drug law rather than inside one of its exemptions. A compounded product from a state-licensed pharmacy and a research-labelled vial from a peptide vendor are different in kind, not in degree.

What to check before you buy

• •Does the seller name a compounding pharmacy? FDA reports fraudulent compounded semaglutide labels naming pharmacies that do not exist, and others naming a real pharmacy that did not make the product³. A named pharmacy is checkable; "our licensed network" is not.
• •Does it state 503A or 503B, in writing? The two carry different manufacturing rules — outsourcing facilities are subject to current good manufacturing practice and 503A pharmacies are not — and different inspectors¹. FDA publishes the registered outsourcing facility list, so a 503B claim can be verified⁹.
• •Base or salt? If the answer is semaglutide sodium or semaglutide acetate, FDA's stated position is that it knows of no lawful basis for compounding with it³.
• •Is the price the real standing price? Prepay tiers, first-month teasers, and required memberships are the three ways a headline number in this category stops being the number you pay. Our semaglutide provider comparison reads each company's own pages for the month-to-month figure, and our cross-board pricing index puts every provider's real price for every compound in one table.

FDA's own summary of the whole category is the fairest ending: compounded drugs "should only be used in patients whose medical needs cannot be met by an FDA-approved drug," and poor compounding practice "can result in serious drug quality problems, such as contamination or a drug that contains too much or too little active ingredient²¹⁰." That risk is not evenly distributed across sellers. It concentrates in exactly the companies that will not tell you who made the vial.